Reuters logo
2 个月前
BRIEF-TapImmune reaches 50 pct patient enrollment benchmark in phase 2 study of novel t-cell vaccine targeting triple-negative breast cancer
2017年6月27日 / 下午1点29分 / 2 个月前

BRIEF-TapImmune reaches 50 pct patient enrollment benchmark in phase 2 study of novel t-cell vaccine targeting triple-negative breast cancer

June 27 (Reuters) - TapImmune Inc

* TapImmune reaches 50% patient enrollment benchmark in phase 2 study of novel t-cell vaccine targeting triple-negative breast cancer

* TapImmune Inc - Enrollment completion anticipated by year end 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below